Single Ascending Dose Safety and Pharmacokinetics of CDRI-97/78: First-in-Human Study of a Novel Antimalarial Drug
Figure 3
Mean plasma concentration-time profile of in vivo active metabolite 97/63 after oral administration of 97/78 at 200 mg single dose to male healthy human volunteers ().
